Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

BACKGROUND: Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced diseas...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:N Engl J Med
Egile Nagusiak: Abou-Alfa, G.K., Meyer, T., Cheng, A.-L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y.H., Park, J.-W., Blanc, J.-F., Bolondi, L., Klümpen, H.-J., Chan, S.L., Zagonel, V., Pressiani, T., Ryu, M.-H., Venook, A.P., Hessel, C., Borgman-Hagey, A.E., Schwab, G., Kelley, R.K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7523244/
https://ncbi.nlm.nih.gov/pubmed/29972759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1717002
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak